The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia

Tumour hypoxia renders cancer cells resistant to cancer therapy, resulting in markedly worse clinical outcomes. To find clinical candidate compounds that reduce hypoxia in tumours, we conduct a high-throughput screen for oxygen consumption rate (OCR) reduction and identify a number of drugs with thi...

Full description

Saved in:

Bibliographic Details
Published in:	Nature communications Vol. 7; no. 1; p. 12308
Main Authors:	Ashton, Thomas M., Fokas, Emmanouil, Kunz-Schughart, Leoni A., Folkes, Lisa K., Anbalagan, Selvakumar, Huether, Melanie, Kelly, Catherine J., Pirovano, Giacomo, Buffa, Francesca M., Hammond, Ester M., Stratford, Michael, Muschel, Ruth J., Higgins, Geoff S., McKenna, William Gillies
Format:	Journal Article
Language:	English
Published:	London Nature Publishing Group UK 25.07.2016 Nature Publishing Group Nature Portfolio
Subjects:	13/106 13/51 14 14/63 631/67/1059 631/67/2327 64/60 Animals Antimalarials - pharmacology Atovaquone - pharmacology Biguanides - pharmacology Cancer therapies Clinical outcomes Drugs Electron Transport Complex III - metabolism FDA approval High-Throughput Screening Assays Humanities and Social Sciences Hypoxia Hypoxia-Inducible Factor 1, alpha Subunit - metabolism Malaria Mice, Inbred BALB C Mice, Nude multidisciplinary Oncology Oxygen consumption Oxygen Consumption - drug effects Pyrimidines - biosynthesis Radiation therapy Radiation Tolerance - drug effects Science Science (multidisciplinary) Signal transduction Spheroids, Cellular - drug effects Spheroids, Cellular - metabolism Spheroids, Cellular - pathology Tumor Cells, Cultured Tumor Hypoxia - drug effects Tumors
ISSN:	2041-1723, 2041-1723
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!